Tandem Diabetes EVP sells small block of shares

Tandem Diabetes Care executive Mark David Novara, EVP & Chief Commercial Officer, sold 2 shares of the company’s common stock in an open-market transaction.

Rhea-AI Filing Summary

Tandem Diabetes Care executive Mark David Novara, EVP & Chief Commercial Officer, sold 2 shares of the company’s common stock in an open-market transaction. The sale occurred at a price of $22.81 per share. After this small sale, he directly holds 35,969 shares of Tandem Diabetes Care common stock.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Novara adopted on December 4, 2025, which is designed to allow insiders to sell shares according to a predetermined schedule.

Insider Trade Summary

Net Seller: 2 shares

Net Sell 1 txn

Insider Novara Mark David

Role EVP & CHIEF COMMERCIAL OFFICER

Sold 2 shs ($45.62)

Type	Security	Shares	Price	Value
Sale	Common Stock	2	$22.81	$45.62

Holdings After Transaction: Common Stock — 35,969 shares (Direct)

Footnotes (1)

1. F1. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tandem Diabetes Care (TNDM) report for Mark David Novara?

Tandem Diabetes Care reported that executive Mark David Novara sold 2 shares of common stock. The open-market sale was reported on Form 4 and reflects a very small change in his overall direct holdings in the company.

At what price were the Tandem Diabetes Care (TNDM) shares sold by Mark David Novara?

Mark David Novara’s reported sale of Tandem Diabetes Care common stock was executed at $22.81 per share. This transaction involved only 2 shares, making it a minor adjustment to his total direct ownership position.

How many Tandem Diabetes Care (TNDM) shares does Mark David Novara hold after the transaction?

After the reported sale, Mark David Novara directly holds 35,969 shares of Tandem Diabetes Care common stock. This figure reflects his remaining direct ownership following the small open-market disposition of 2 shares at $22.81 per share.

Was the Tandem Diabetes Care (TNDM) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states the shares were sold under a Rule 10b5-1 trading plan adopted by Mark David Novara on December 4, 2025. Such plans allow insiders to schedule trades in advance under predetermined conditions.

Who is the insider involved in the latest Tandem Diabetes Care (TNDM) Form 4 filing?

The insider is Mark David Novara, Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care. He reported an open-market sale of 2 shares of common stock at $22.81 per share under a pre-arranged Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Novara Mark David

(Last) (First) (Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CHIEF COMMERCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S(1)		2	D	$22.81	35,969	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.

Remarks:

	/s/ Shannon M. Hansen, Attorney-in-Fact for Mark D. Novara	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.